RxDoctor Payments Data

Dana Tucker, APRN

Women's Health · Augusta, KYNPI 1407173446

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 26.5% of the total.

$980in general payments, 2019–2025

Across 55 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • Astellas Pharma US Inc$236
  • Exact Sciences$84
  • Agile Therapeutics, Inc.$65
  • Medline Industries LP$63
  • Merck$59
  • plus $213 from 8 others

What the payments were for

  • Food & beverage$90592%
  • Education$758%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$980 in reported general payments places this provider in the 60th percentile of 96 women's health providers in Kentucky.

See all women's health providers in Kentucky

Medicare billing

Part B allowed, 2024
$356
Medicare patients
13
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet13$2,845
Medroxyprogesterone Acetate14$286
Estradiol15$158
Fluconazole21$72
Alendronate Sodium26$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPrempro$30$2,84513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 96 women's health providers in Kentucky.

Other women's health in Augusta

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →